Home » Newsletters » BioWorld Science

BioWorld Science

July 28, 2006

View Archived Issues

Genentech and Inotek collaborate on PARP inhibitors for cancer

Kos reports findings from flush provocation study of Niaspan CF with aspirin

Withania somnifera improves muscle strength in elderly subjects

Intravenous immunoglobulin therapy for AD

Elan present novel gamma secretase inhibitors

Meiji Seika signs license agreement for progesterone modulator with Tokai

NCX-4016 to be advanced as insulin sensitizing agent for type 2 diabetes

Liponex prepares for phase I/II study of CRD-5 for dyslipidemia

Xechem accelerates construction of Nicosan production facility

ComGenex changes name to AMRI Hungary

Avalon and ChemDiv collaboration to discover oncology therapeutics

Calando selects Agilent for siRNA production

SPA completed for confirmatory study of Genasense in CLL

Orphan drug status for novel antifolate PDX in T-cell lymphoma

Oral nalmefene demonstrates positive results in pilot smoking cessation study

Quadramet studied in phase III trial for osteoblastic metastases

New phase II study for Genz-112638 in Gaucher's disease

LL-4218 cleared to begin phase II trials for psoriasis in India

Agents for dermatological conditions prepared and tested

Recent patents impart new therapeutics for cardiovascular disorders

New tumor necrosis factor-alpha inhibitors for immunological disorders reported by 4 AZA Bioscience

NDA filed for Xyzal

Zanitek receives German approval

GSK files fluticasone furoate for seasonal and perennial rhinitis in U.S. and E.U.

Improved liver transplantation outcome with novel iNOS inhibitor, FK-330

JAK3 inhibition with R-935 prevents organ rejection in rat heart transplant model

Clioquinol analogue shows improved cognition in animal models of AD and positive phase I results

Potential benefit of pomegranate juice in slowing prostate cancer progression

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...